226 related articles for article (PubMed ID: 22278975)
1. Diarylheterocycle core ring features effect in selective COX-1 inhibition.
Perrone MG; Vitale P; Malerba P; Altomare A; Rizzi R; Lavecchia A; Di Giovanni C; Novellino E; Scilimati A
ChemMedChem; 2012 Apr; 7(4):629-41. PubMed ID: 22278975
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors.
Vitale P; Tacconelli S; Perrone MG; Malerba P; Simone L; Scilimati A; Lavecchia A; Dovizio M; Marcantoni E; Bruno A; Patrignani P
J Med Chem; 2013 Jun; 56(11):4277-99. PubMed ID: 23651359
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).
Cingolani G; Panella A; Perrone MG; Vitale P; Di Mauro G; Fortuna CG; Armen RS; Ferorelli S; Smith WL; Scilimati A
Eur J Med Chem; 2017 Sep; 138():661-668. PubMed ID: 28710965
[TBL] [Abstract][Full Text] [Related]
4. 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
Ranatunge RR; Earl RA; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Schwalb DJ; Young DV; Zemtseva IS
Bioorg Med Chem Lett; 2004 Dec; 14(24):6049-52. PubMed ID: 15546727
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors.
Eren G; Unlü S; Nuñez MT; Labeaga L; Ledo F; Entrena A; Banoğlu E; Costantino G; Sahin MF
Bioorg Med Chem; 2010 Sep; 18(17):6367-76. PubMed ID: 20692174
[TBL] [Abstract][Full Text] [Related]
6. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.
Vitale P; Perrone MG; Malerba P; Lavecchia A; Scilimati A
Eur J Med Chem; 2014 Mar; 74():606-18. PubMed ID: 24531199
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
Praveen Rao PN; Amini M; Li H; Habeeb AG; Knaus EE
J Med Chem; 2003 Nov; 46(23):4872-82. PubMed ID: 14584938
[TBL] [Abstract][Full Text] [Related]
8. Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs).
Perrone MG; Vitale P; Panella A; Ferorelli S; Contino M; Lavecchia A; Scilimati A
ChemMedChem; 2016 Jun; 11(11):1172-87. PubMed ID: 27136372
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 1,3-diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azido pharmacophore as cyclooxygenase-1/-2 inhibitors.
Zarghi A; Zebardast T; Hakimion F; Shirazi FH; Rao PN; Knaus EE
Bioorg Med Chem; 2006 Oct; 14(20):7044-50. PubMed ID: 16798002
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Apr; 13(7):2459-68. PubMed ID: 15755648
[TBL] [Abstract][Full Text] [Related]
11. Trimethyl-4-oxo-4,5,6,7-tetrahydroindazole-1-acetic acid: a new lead compound with selective COX-2 inhibitory activity.
Abdel-Rahman HM; Ozadali K
Arch Pharm (Weinheim); 2012 Nov; 345(11):878-83. PubMed ID: 22907715
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors.
Zarghi A; Kakhgi S; Hadipoor A; Daraee B; Dadrass OG; Hedayati M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1336-9. PubMed ID: 18226898
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
Abdel-Aziz AA; ElTahir KE; Asiri YA
Eur J Med Chem; 2011 May; 46(5):1648-55. PubMed ID: 21388719
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of new 1,3-benzthiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.
Zarghi A; Zebardast T; Daraie B; Hedayati M
Bioorg Med Chem; 2009 Aug; 17(15):5369-73. PubMed ID: 19596198
[TBL] [Abstract][Full Text] [Related]
15. Design of novel N-phenylnicotinamides as selective cyclooxygenase-1 inhibitors.
Shi L; Li ZL; Yang Y; Zhu ZW; Zhu HL
Bioorg Med Chem Lett; 2011 Jan; 21(1):121-4. PubMed ID: 21144750
[TBL] [Abstract][Full Text] [Related]
16. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal.
Di Nunno L; Vitale P; Scilimati A; Tacconelli S; Patrignani P
J Med Chem; 2004 Sep; 47(20):4881-90. PubMed ID: 15369392
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase-2 inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Dec; 13(23):6425-34. PubMed ID: 16099663
[TBL] [Abstract][Full Text] [Related]
18. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
Di Fiore A; Pedone C; D'Ambrosio K; Scozzafava A; De Simone G; Supuran CT
Bioorg Med Chem Lett; 2006 Jan; 16(2):437-42. PubMed ID: 16290146
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-1 and cyclooxygenase-2 inhibition of novel 1,2-disubstituted imidazoles.
Handler N; Jaeger W; Kuen-Krismer B; Erker T
Arch Pharm (Weinheim); 2005 Dec; 338(12):602-4. PubMed ID: 16353278
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of dithiolethiones as novel cyclooxygenase inhibitors.
Zanatta SD; Manallack DT; Jarrott B; Williams SJ
Bioorg Med Chem Lett; 2009 Jan; 19(2):459-61. PubMed ID: 19056264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
